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Hypocalcemia characterized by critically low calcium levels may prompt urgent hospitalization and calcium replacement to prevent potentially life-threatening consequences. In 1995 and 1999, respectively, Normann et al and Lin et al described the interference of gadodiamide, a chelate of gadolinium, with the colorimetric assay for serum calcium resulting in spurious hypocalcemia. More recently, a retrospective study by Prince et al implicated gadodiamide as the cause of critically low calcium levels documented in hospital medical records. However, given the retrospective design of the study, this hypothesis could not be confirmed. Further studies have shown that another chelate of gadolinium, gadoversetamide, produces similar interference with calcium in the colorimetric assay. The remaining clinically available chelates, gadoteridol and gadopentetate dimeglumine, have not been associated with this phenomenon.
Current data suggest that gadolinium chelates are used in 20% to 25% of all magnetic resonance studies, a practice that is likely to result in an increase in the incidence of gadolinium-induced spurious hypocalcemia. This prediction is bolstered by the increasing number of recent reports in the literature. 
Spurious Hypocalcemia After Gadodiamide Administration
Gadodiamide contrast MRI of carotid arteries.
Discussion
Gadolinium chelates are frequently used as contrast agents during magnetic resonance imaging and angiography. Clinician awareness of gadolinium-induced spurious hypocalcemia must improve in this era of increasing use of magnetic resonance imaging and angiography. In the study by Prince et al, this phenomenon occurred in approximately 4% of the examinations reviewed, and in more than one half of these patients (59%), calcium levels were in the critical range. However, their study may have overestimated the incidence given the presumed comorbidities in this group of hospitalized patients. Factors that affect serum concentration of the gadolinium, such as increased dose, decreased elapsed time since administration, and reduced renal function, were associated with an increased risk of false hypocalcemia. The time course for this phenomenon reportedly ranged from immediately after gadolinium infusion to more than 24 hours after administration, depending on the patient's renal function. In patients with normal renal function, the interference disappeared within 12 hours, but in the presence of renal insufficiency, it persisted for more than 24 hours and in some instances up to several days. Additionally, the greatest errors in calcium levels were noted in patients in whom calcium levels were obtained immediately after chelate infusion and in those receiving higher doses of gadodiamide (≥0.2 mmol/kg). Data from animal studies confirm the transient nature of this phenomenon and its association with the dose of chelate administered.
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Magnetic Resonance Imager
Williams et al recently reported a case of a 78-year-old man with a critically low serum calcium level (5.8 mg/dL). This patient had an elevated creatinine level of 1.5 mg/dL (reference range, 0.9-1.4 mg/dL) and had initial serum calcium measured only 20 minutes after gadodiamide administration, factors that could have contributed to the critically low calcium level as measured by a colorimetric assay (see Table 1 ). The low serum calcium level was confirmed by repeat testing at a second laboratory, also using a colorimetric assay. However, a normal calcium level was obtained from the same specimen measured by atomic absorption spectroscopy, and a normal ionized calcium measurement was also obtained on the patient. Gadolinium-induced spurious hypocalcemia should be considered in the setting of a low calcium value, recent administration of the chelates gadodiamide or gadoversetamide, and absent clinical signs or symptoms of hypocalcemia. Clinicians should recognize that without marked hypoalbuminemia, critically low calcium levels are improbable in asymptomatic patients. Spurious hypocalcemia can be confirmed by measurement of either ionized calcium or total serum calcium determined by any spectroscopic method (such as ICP-OES). Alternatively, delaying the performance of nonurgent laboratory studies after gadolinium use will reduce the likelihood of finding spuriously low calcium levels. 
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Question:
Does gadolinium administration affect tests other than calcium?
Answer:
Yes. Gadolinium is known to interfere with most metals tests. At the necessary levels for contrast media, gadolinium ions distort the measured concentration of the analytes of interest by direct spectral overlap, destabilize the internal standard, or overload the instrument's detection system. If gadolinium-containing contrast media has been administered, a specimen for metals testing cannot be collected for 48 hours.
Conclusion
Increasing the awareness of spurious hypocalcemia within the general medical community may reduce unnecessary extended hospitalizations, inappropriate work-ups, and potentially dangerous and unnecessary interventions, consistent with the recommendation of the Institute of Medicine's report on patient safety. When evaluating patients for total calcium measurement following gadolinium administration, physicians must wait 48 hours before drawing the specimen. However, if a medical situation arises in which the calcium level must be assessed before the gadolinium has had time to clear, an ionized calcium test can be ordered or special arrangements can be made with MML to have the patient's specimen tested using ICP-OES.
Adapted from Mayo Clinic Proceedings December 2005;80(12):1655-1657. References and case information omitted. The complete article is available online at URL http://www.mayoclinicproceedings.com.
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Hepatitis New Tests Offered
Mayo Medical Laboratories recently introduced 6 new hepatitis tests. The relevant test information is listed below. 
Hepatitis B Virus
Paraneoplastic Autoantibody Evaluation Change
MML's #83380 Paraneoplastic Autoantibody Evaluation was designed to facilitate expert interpretation of autoantibody profiles in the evaluation of patients who are suspected to have paraneoplastic neurological autoimmunity. The tests that are included in this evaluation enable sensitive and efficient detection of autoantibodies directed at:
• neuronal, glial, and muscle plasma membrane ion channels • neuronal, muscle and glial cytoplasmic antigens • neuronal nuclear antigens that currently are encountered most frequently in patients with neurological autoimmunity initiated by systemic tumor-associated antigens (eg, in adults with lung, breast or ovarian carcinoma, thymoma or Hodgkin lymphoma, and in pediatric patients with neuroblastoma, thymoma or chondroblastoma, and sometimes with other cancers)
These antibodies usually do not occur in isolation, but as a group whose profile is predictive of a specific cancer type, rather than a specific neurologic syndrome. Thus, the tests are always performed in algorithmic fashion, and reflex tests are done as dictated by the individual patient's emerging autoantibody profile. Some of these autoantibodies are encountered in the context of graft-versus-host disease, or as a complication of D-penicillamine therapy.
Recently, the test algorithm was changed to:
• Include automatic reflexing to #83107 CRMP-5-IgG Western Blot (performed at an additional charge) when acetylcholine receptor (AChR) ganglionic neuronal antibody is ≥0.03. This reflex has been added because AChR ganglionic neuronal antibody is a recognized marker of thymoma and lung carcinoma, for which CRMP-5-IgG also serves as a sensitive confirmatory marker.
• Discontinue reflexing to paraneoplastic autoantibody Western blot (using native neuronal proteins), except when a particular neuronal nuclear or cytoplasmic autoantibody is suspected in the initial immunofluorescence screening, or when coexisting nonorgan-specific autoantibodies preclude accurate immunofluorescence interpretation. The currently optimized immunofluorescence assay is a more sensitive test than the paraneoplastic autoantibody Western blot, eliminating the need for the reflex.
Note: The Western blot assay using recombinant human CRMP-5 is more sensitive than immunofluorescence for detecting CRMP-5-IgG. In follow-up of patients already known to be seropositive for CRMP-5-IgG in this laboratory, #83107 CRMP-5-IgG Western Blot is automatically performed. As well, if the IFA pattern suggests CRMP-5, #83107 CRMP-5-IgG Western Blot is automatically performed. The #83107 CRMP-5-IgG Western Blot is highly recommended for evaluating patients with subacute unexplained basal ganglionic disorders (chorea/Parkinsonism/ hemi-ballismus), cranial neuropathies (particularly loss of vision, smell or taste), myelopathies, and radiculoplexopathies.
The revised algorithm is on page 7.
